Brazil Adds Edaravone to SUS for Early-Stage ALS Treatment

Eligibility and Implementation Timeline

According to the ministry’s directive, the new treatment is specifically designated for patients classified in grades 1 or 2 of the disease who have experienced symptoms for a duration of two years or less. Following the publication of the portaria, technical areas within the Ministry of Health have a maximum window of 180 days to implement the supply of the medication within the public network (jornaldebrasilia.com.br). Medical professionals may prescribe edaravone either as a standalone therapy or in combination with riluzol, the current standard treatment, depending on clinical evaluation.

Mechanism of Action and Clinical Evidence

The incorporation of edaravone followed a recommendation from the National Commission for the Incorporation of Technologies in the SUS (Conitec), which evaluated the drug’s efficacy, safety, and cost-benefit profile. Technical-scientific reports indicate that edaravone functions by reducing oxidative stress, a biological mechanism linked to the degeneration of motor neurons. While the medication does not cure ALS, evidence reviewed by Conitec suggests it effectively slows the functional decline of patients (noticias.uol.com.br). The safety profile of the drug is considered satisfactory by regulatory standards.

Understanding ALS and Multidisciplinary Care

ALS is a rare, progressive neurodegenerative disease that affects neurons responsible for voluntary movement. In Brazil, the prevalence is estimated at 1.2 cases per 100,000 inhabitants. While the disease generally leaves cognitive and sensory functions—such as memory, intelligence, and the five senses—intact, it leads to a gradual loss of muscle strength. This progression can eventually impair a patient’s ability to walk, speak, swallow, and breathe. According to technical assessments, respiratory failure is the primary cause of death, typically occurring between three and five years after symptom onset (brasil247.com).

Health authorities emphasize that medication is only one component of the management of ALS. Comprehensive care remains centered on a multidisciplinary approach designed to preserve functionality and quality of life.

• Neurological monitoring
• Physical therapy
• Speech therapy
• Occupational therapy
• Nutritional assistance
• Respiratory care
• Psychological support

Diagnostic Challenges

There is no single definitive test for ALS. Diagnosis is performed by neurologists through a combination of clinical evaluation, patient history, and diagnostic tests—such as electromyography, magnetic resonance imaging, and laboratory exams—to exclude other conditions with similar symptoms. The disease is most frequently diagnosed in individuals between 55 and 75 years old, with studies suggesting an average onset age of approximately 52. Statistics indicate that men are affected about 1.5 times more often than women, and while a small fraction of cases are hereditary, more than 90% of diagnoses have no known cause (jb.com.br).